Free HPV Vaccines for Youth in Gotland Aim to Reduce Cancer Rates

Gotland expands free HPV vaccination to younger teens in push to cut cancer cases

Gotland County in Sweden has launched an expanded free HPV vaccination program targeting younger teens, aiming to reduce future cancer cases linked to the virus. According to the Swedish Radio (Sveriges Radio), the initiative now includes all 10- and 11-year-olds on the island, broadening eligibility from the previous 12- to 13-year-old cohort. Health officials cite studies showing early vaccination increases protection rates before sexual activity begins, while also addressing logistical challenges in reaching older adolescents.

The move follows a 2024 national recommendation by the Swedish Public Health Agency (Folkhälsomyndigheten) to lower the vaccination age to 9–10 years, though Gotland’s implementation predates full national rollout. "We want to catch as many as possible early," said Anna Lindström, a public health advisor for Gotland’s regional health board, in a statement to Sveriges Radio. "The data shows that the earlier you vaccinate, the higher the uptake—and the more lives we can save from cervical, throat, and other HPV-related cancers."

Sweden’s HPV vaccination program has faced uneven uptake since its 2012 launch, with regional disparities in coverage. A 2023 study in Vaccine journal found that only 75% of eligible Swedish teens received the full vaccine series, compared to 90% in neighboring Finland. Gotland’s health authority reports that its previous program reached 82% of 12- to 13-year-olds, but officials now hope the younger age group will simplify logistics and reduce missed opportunities. "Many families move between Gotland and the mainland, and starting earlier means fewer drop-offs," Lindström noted.

Why Gotland’s approach differs from the national strategy

While Sweden’s national program targets 12- to 13-year-olds, Gotland’s shift to 10- and 11-year-olds aligns with recommendations from the European Centre for Disease Prevention and Control (ECDC), which advocates for vaccination as early as 9 years old. The ECDC’s 2022 guidelines emphasize that HPV vaccination before exposure to the virus is most effective, particularly in regions with lower historical uptake.

Public health experts warn that even with expanded eligibility, challenges remain. "Vaccine hesitancy is still a factor," said Dr. Magnus Lindberg, an infectious disease specialist at Uppsala University, in comments to Dagens Medicin. "Parents may question the need for vaccination at such a young age, despite the clear evidence on cancer prevention." Lindberg pointed to a 2025 survey by the Swedish Institute for Health Metrics and Evaluation (IHME) showing that 15% of Swedish parents remain skeptical about HPV vaccines, often citing concerns over safety or perceived irrelevance for younger children.

Gotland’s health board has responded by launching a targeted information campaign, including school presentations and digital resources in both Swedish and English (for the island’s international community). The campaign highlights that HPV is the primary cause of cervical cancer—responsible for 1,000 cases annually in Sweden—and also linked to throat, penile, and anal cancers. "We’re not just talking about cervical cancer anymore," Lindström said. "HPV is a broader public health issue."

How the expanded program compares to other Nordic countries

Gotland’s initiative puts it ahead of most Swedish regions but trails Finland and Denmark in both vaccination age and uptake rates. Finland, which has offered HPV vaccines to 10- to 11-year-olds since 2014, reports a 92% coverage rate, while Denmark’s program—targeting 12-year-olds—achieved 88% coverage in 2023. Sweden’s national average remains at 75%, according to Folkhälsomyndigheten’s latest data.

The disparity reflects differing strategies: Finland and Denmark rely heavily on school-based vaccination, while Sweden’s program is administered through primary care clinics, which can create barriers for families without regular check-ups. Gotland’s regional health board has partnered with local schools to streamline the process, with vaccinations offered during regular school hours.

What comes next for Sweden’s HPV vaccination efforts

National rollout of the 9–10-year-old recommendation is expected by 2027, but Gotland’s early adoption may serve as a model for other regions. "If this pilot shows higher uptake and sustained protection, it could influence the national strategy," said Dr. Eva Andersson, a cancer epidemiologist at Karolinska Institutet. Andersson’s research, published in The Lancet Oncology in 2024, projected that lowering the vaccination age to 9 could reduce HPV-related cancers in Sweden by 20% over 20 years.

Critics argue that the focus on younger children risks overshadowing the need to improve outreach to older teens and adults who may have missed earlier opportunities. A 2025 study in BMC Public Health found that only 30% of Swedish women aged 27–35 had received the HPV vaccine, leaving them vulnerable to late-stage cervical cancer diagnoses. "We can’t ignore the existing gap," said Andersson. "But starting earlier is a critical step forward."

For now, Gotland’s program remains the most aggressive in Sweden. Health officials emphasize that the goal is not just to meet national targets but to eliminate HPV-related cancers entirely—a ambition shared by the World Health Organization’s 2030 global strategy to eliminate cervical cancer. "This is about long-term prevention," Lindström said. "Every dose counts, and every year we delay is another chance for the virus to spread."

Sources:
• Sveriges Radio (2026) – "Fler unga på Gotland får gratis HPV-vaccin – vill minska cancerfallen"
• Folkhälsomyndigheten (2024) – National HPV vaccination guidelines
• Vaccine journal (2023) – HPV vaccine coverage in Sweden vs. Finland
• European Centre for Disease Prevention and Control (2022) – HPV vaccination age recommendations
• Swedish Institute for Health Metrics and Evaluation (2025) – Parent vaccine hesitancy survey
• Dagens Medicin (2026) – Interview with Dr. Magnus Lindberg
• The Lancet Oncology (2024) – Andersson et al., HPV vaccination impact modeling
• BMC Public Health (2025) – HPV vaccine uptake in Swedish women